BT062, An Antibody-Drug Conjugate Directed Against CD138, Shows Clinical Activity in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma
Year: 2011
Type: article
Study design: Clinical Trial
Source: Blood
Authors: Sundar Jagannath, Asher Chanan-Khan, Leonard T. Heffner, David Avigan, Todd M. Zimmerman, Sagar Lonial, Robert J. Lutz, Andre Engling, Christoph Uherek, Frank Osterroth, Markus Ruehle, Michelle A. Beelitz, Gabriele Niemann, Andrea Wartenberg-Demand, Thomas Haeder, Kenneth C. Anderson, Nikhil C. Munshi
Institutions: Icahn School of Medicine at Mount Sinai, Roswell Park Comprehensive Cancer Center, Winship Cancer Institute, Beth Israel Deaconess Medical Center, University of Chicago, Emory University, ImmunoGen (United States), Biotest (Germany), Biotest (United States), Harvard University, Dana-Farber Cancer Institute, Dana-Farber/Harvard Cancer Center
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2499607043